Last reviewed · How we verify
Triatec HCT 5
Triatec HCT 5 is a Small molecule drug developed by Heart Care Foundation. It is currently FDA-approved.
Triatec HCT 5 is a marketed drug by Heart Care Foundation with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a significant competitive advantage due to its patent protection until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Triatec HCT 5 |
|---|---|
| Sponsor | Heart Care Foundation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triatec HCT 5 CI brief — competitive landscape report
- Triatec HCT 5 updates RSS · CI watch RSS
- Heart Care Foundation portfolio CI
Frequently asked questions about Triatec HCT 5
What is Triatec HCT 5?
Who makes Triatec HCT 5?
What development phase is Triatec HCT 5 in?
Related
- Manufacturer: Heart Care Foundation — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing